MeDioStar

K240816 · Asclepion Laser Technologies GmbH · GEX · Apr 23, 2024 · General, Plastic Surgery

Device Facts

• Record ID: K240816
• Device Name: MeDioStar
• Applicant: Asclepion Laser Technologies GmbH
• Product Code: GEX · General, Plastic Surgery
• Decision Date: Apr 23, 2024
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The MeDioStar laser system is intended for surgical, aesthetic applications in the medical specialties of general and plastic surgery and dermatology. The MeDioStar laser system is intended for the treatment of benign vascular lesions. The MeDioStar laser system is intended for the treatment of benign pigmented lesions. The MeDioStar laser system is intended for hair reduction defined as reduced hair growth with or without maintenance when measured at 6, 9 and 12 months ..

Device Story

MeDioStar is a pulsed diode laser system for surgical and aesthetic applications. Device consists of a main console, interchangeable handpieces, and a footswitch. Operator (clinician) selects parameters via touchscreen display; software controls device functions. Laser emits wavelengths between 755–1060 nm. During operation, handpiece is in contact with patient skin. Device delivers laser energy to target tissue for treatment of benign vascular/pigmented lesions and hair reduction. Output parameters include pulse duration up to 400 ms, repetition rate up to 20 Hz, and max fluence of 210 J/cm². Clinical benefit includes effective hair reduction and treatment of benign skin lesions. Device is intended for professional use in clinical settings.

Clinical Evidence

No clinical data provided. Substantial equivalence is supported by bench testing, including electrical safety (IEC 60601-1), electromagnetic compatibility (IEC 60601-1-2), laser safety (IEC 60601-2-22), software validation (IEC 62304), usability engineering (IEC 62366-1), and risk management (ISO 14971). Biocompatibility is established via predicate device comparison.

Technological Characteristics

Diode laser system; wavelength 755–1060 nm; max fluence 210 J/cm²; pulse duration up to 400 ms; repetition rate up to 20 Hz. System includes main console, touchscreen interface, and contact handpieces. Complies with IEC 60601-1, IEC 60601-1-2, IEC 60601-2-22, IEC 62304, IEC 62366-1, and ISO 14971.

Indications for Use

Indicated for surgical, aesthetic, and cosmetic applications in general surgery, plastic surgery, and dermatology, including treatment of benign vascular lesions, benign pigmented lesions, and hair reduction.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• MeDioStar (K192483)

Reference Devices

• LightSheer Infinity (K170179)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logos of the Department of Health and Human Services and the Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the text "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue.

April 23, 2024

Asclepion Laser Technologies GmbH Tom Gruender RA Manager Bruesseler Strasse 10 Jena, 07745 Germany

Re: K240816

Trade/Device Name: MeDioStar Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: March 21, 2024 Received: March 25, 2024

Dear Tom Gruender:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn).

{2}------------------------------------------------

Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/deviceadvice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Tanisha L. Digitally signed by Hithe -S 13:55:03 -04'00'

Tanisha Hithe Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K240816

Device Name MeDioStar

Indications for Use (Describe)

The MeDioStar laser system is intended for surgical, aesthetic applications in the medical specialties of general and plastic surgery and dermatology.

The MeDioStar laser system is intended for the treatment of benign vascular lesions.

The MeDioStar laser system is intended for the treatment of benign pigmented lesions.

The MeDioStar laser system is intended for hair reduction defined as reduced hair growth with or without maintenance when measured at 6, 9 and 12 months ..

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|

> Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

## 510(k) Summary for K240816

| Applicant /<br>Manufacturer | Asclepion Laser Technologies GmbH |
|-----------------------------|-----------------------------------------------------------------------------------------|
| Name and Address: | Bruesseler Strasse 10, 07745 Jena - Germany |
| 510(k) Contact Person: | Mr. Tom Gruender<br>Regulatory Affairs Manager<br>Tel.: [phone] |
| Date Prepared: | E-Mail: [e-mail]<br>20/02/2024 |
| Trade Name: | MeDioStar |
| Common Name: | MeDioStar Diode Laser device |
| Classification: | Class II |
| Classification Name: | Laser surgical instrument for use in general and plastic surgery<br>and in dermatology. |
| Regulation Number: | 21 CFR 878.4810 |
| Product Code: | GEX |
| Main Predicate Device | MeDioStar (K192483), Asclepion Laser Technologies GmbH |
| Reference Device | LightSheer Infinity (K170179), Lumenis Ltd. |

Performance Standards:

There are no mandatory performance standards for this device.

## Description of the device:

The modified MeDioStar is a pulsed diode laser emitting a wavelength of 755 - 1060 nm that is operated with a handpiece in contact with the skin. The system comprises a main console unit, a handpiece and is triggered by means of a footswitch. There are several handpieces, the user can choose from. Moreover, a specific software controls the device functions and allows the user selections through the touchscreen display.

### Description of the modifications:

The laser is a modification to previously cleared MeDioStar due to some technical modifications concerning the wavelength range.

{5}------------------------------------------------

The subject device has the same technological characteristics (material, components, energy source) as the predicate device except for the differences shown in the table below:

| | Main<br>Predicate Device | Reference<br>Predicate Device | Subject device |
|-------------|--------------------------|-------------------------------|----------------|
| | MeDioStar | LightSheer Infinity | MeDioStar |
| 510k number | K192483 | K170179 | - |
| Wavelength | 755 – 950 nm | 805 – 1060 nm | 755 – 1060 nm |

The modified device has the same intended use of the unmodified device MeDioStar. Moreover, the intended use of the modified device, as described in its labeling, has not changed as a result of the modifications.

Based on the nature of the changes implemented, the device underwent and successfully passed performance testing and software verifications and validation according to the relevant standards.

### Indications for Use:

The MeDioStar laser system is intended for surgical, aesthetic and cosmetic applications in the medical specialties of general and plastic surgery and dermatology.

The MeDioStar laser system is intended for the treatment of benign vascular lesions.

The MeDioStar laser system is intended for the treatment of benign pigmented lesions.

The MeDioStar laser system is intended for hair removal, permanent hair reduction defined as reduced hair growth with or without maintenance when measured at 6, 9 and 12 months..

### Technological Characteristics Comparison

| | Main<br>Predicate Device | Reference<br>Predicate Device | Subject device |
|-----------------|--------------------------|-------------------------------|----------------|
| | MeDioStar | LightSheer Infinity | MeDioStar |
| 510k number | K192483 | K170179 | - |
| Device Type | Diode Laser | Diode Laser | Diode Laser |
| Wavelength | 755 – 950 nm | 805 – 1060 nm | 755 – 1060 nm |
| Pulse Duration | Up to 400 ms | Up to 400 ms | Up to 400 ms |
| Repetition Rate | Up to 20 Hz | Up to 3 Hz | Up to 20 Hz |
| Max fluence | 210 J/cm² | 80 J/cm² | 210 J/cm² |

{6}------------------------------------------------

| Handpiece Port | Double | Single | Double |
|----------------|--------|--------|--------|
|----------------|--------|--------|--------|

### Non clinical Performance Data:

The following performance data were applied in support of the substantial equivalence determination:

- ISO 60601-1: Medical electrical equipment Part 1: General requirements for safety and essential . performance
- . ISO 60601-1-2 Medical electrical equipment – Part 1-2: General requirements for safety and essential performance – Collateral standard: Electromagnetic compatibility – Requirements and tests
- IEC 62304: Medical Device Software – Software life cycle processes
- IEC 62366-1: Medical devices Application of usability engineering to medical devices ●
- IEC 60601-2-22: Medical electrical equipment – Part 2: Particular requirements for the safety of diagnostic and therapeutic laser equipment
- . ISO 14971: Medical devices – Application of risk management to medical devices
- . Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices".

MeDioStar passed all the required testing and is in compliance will all applicable sections of the abovementioned performance standards.

### Biocompatibility:

The biocompatibility of MeDioStar is established based on the predicate devices.

### Comparison with predicate device:

The subject and predicate devices have intended use and the same fundamental scientific technology. Any minor difference does not raise concern about safety and effectiveness.

### Conclusions

The differences in the indications for use and technological characteristics between the subject and predicate device do not raise new types of questions regarding safety and effectiveness, and the subject device is as safe, as effective, and performs as well as the legally marketed predicate devices.